HSV-TK engineered donor lymphocytes add-backs reduce late mortality and improve survival of high risk acute leukemia after haplo-HSCT: Results of a phase II multicenter trial.

Ciceri, Fabio; Bonini, MARIA CHIARA; Stanghellini, Mtl; Bondanza, Attilio; Magnani, Z; Perna, S; Bernardi, M; Peccatori, J; Pescarollo, A; Servida, P; Crippa, F; Callegaro, L; Salomoni, M; Turchetto, L; Toma, S; Bruzzi, P; Castagna, L; Santoro, A; Apperley, J; Slavin, S; Colombi, S; Gallo Stampino, C; Bregni, M; Bordignon, Claudio